A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Introduction: Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested the safety and efficacy of vorolanib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived...

Full description

Bibliographic Details
Main Authors: Kathryn E. Beckermann, MD, PhD, Christine M. Bestvina, MD, Badi El Osta, MD, Rachel E. Sanborn, MD, Hossein Borghaei, MD, Philip Edward Lammers, MD, MSCI, Giovanni Selvaggi, MD, Jennifer G. Whisenant, PhD, Ellen Heimann-Nichols, MBA, Lynne Berry, PhD, Chih-Yuan Hsu, PhD, Yu Shyr, PhD, Leora Horn, MD, MSc, MHPE, Heather Wakelee, MD, FASCO
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
Thymic
Small cell
Anti-angiogenic
Nivolumab
PD-1
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001625

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001625

Similar Items